Unlock instant, AI-driven research and patent intelligence for your innovation.

shRNA for for knocking down long-chain non-coding RNAMIR205HG in targeted manner and application of shRNA

A targeted and sequence-based technology, applied in the direction of retroRNA virus, DNA/RNA fragments, applications, etc., can solve the problem that the effect and mechanism of breast cancer response to estrogen have not been reported, and achieve the promotion of ER protein degradation, inhibition of The effect of responsiveness

Active Publication Date: 2021-11-16
CHINA PHARM UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although the high expression of lncRNA MIR205HG can promote the occurrence, development, and metastasis of various cancers as described in the above literature, but the regulation of lncRNA MIR205HG on ER + The role and mechanism of breast cancer in response to estrogen have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • shRNA for for knocking down long-chain non-coding RNAMIR205HG in targeted manner and application of shRNA
  • shRNA for for knocking down long-chain non-coding RNAMIR205HG in targeted manner and application of shRNA
  • shRNA for for knocking down long-chain non-coding RNAMIR205HG in targeted manner and application of shRNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Construction of a MCF7 cell line that reduces the expression of lncRNA-MIR205HG

[0032] 1. Materials

[0033] 1.1 Plasmids and cells

[0034] The lentivirus packaging system used in the present invention is PLKO.1 vector plasmid, pMDG packaging plasmid, psPAX2 packaging plasmid, PRTR packaging plasmid; ER +Breast cancer cell line MCF7 and human embryonic kidney epithelial cells (293T) were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. In the DMEM medium of penicillin (100 μg / mL) and penicillin (100 U / mL), the culture conditions were 37°C, 5% CO 2 .

[0035] 1.2 Reagents

[0036] Restriction endonucleases EcoRI and AgeI, T4 DNA ligase, and competent DH5α were purchased from FermentasMBI Company of the United States; Plasmid Mini Kit I was purchased from OMEGA Company of the United States; plasmids were transfected with Lipofectamine TM 2000 was purchased from Invitrogen Company of the United States; Taq DNA polymerase was purc...

example 2

[0058] Example 2: Validation of lncRNA-MIR205HG in MCF7-KD-MIR205HG cell line and normal MCF7 cell line

[0059] 1. Materials

[0060] 1.1 cells

[0061] The MCF7 cell culture method used in the experiment is the same as that in Example 1.

[0062] 1.2 Reagents

[0063] EDTA-containing trypsin digestion solution, purchased from Shanghai Beyond Biotechnology Research Institute; Reagent was purchased from Invitrogen Company of the United States; Reverse Transcription Kit (DDR037A) Nanjing Nuoweizan Biotechnology Co., Ltd. SYRB Premix Ex Taq for real-time quantitative PCR (polymerase chain reaction) TM (TliRNaseH Plus) kit was produced by Nanjing Novizan Biological Co., Ltd. Real-time PCR specific primers were synthesized by Nanjing GenScript Biotechnology Co., Ltd.

[0064] 2. Method

[0065] 2.1 Extraction of total RNA

[0066] Take the constructed MCF7 cell line as the object, culture it in a 60cm dish, and when the cells grow to 70%-80% density, digest the cells with...

Embodiment 3

[0075] Example 3: Application of LncRNA-MIR205HG in the Estrogen Response Process of MCF7 Cells

[0076] 1. Materials

[0077] 1.1 cells

[0078] The control group MCF7 cell line and MCF7-KD-MIE205HG cell line used in the experiment are the same as in Example 2.

[0079] 1.2 Reagents

[0080] Real-Time PCR reagents were the same as in Example 2; estrogen was purchased from Sigma; DMEM medium without phenol red was purchased from Gibco; CF serum was purchased from Gibco; EDTA-free trypsin was purchased from KGI; apoptosis , Periodic detection kits were purchased from KGI Company; CCK8 detection kits were purchased from Biyuntian Company.

[0081] 2. Method

[0082] 2.1 Real-Time PCR experiment

[0083] 2.1.1 Cell estrogen-free treatment and stimulation Take the established MCF7 cell line as the object, culture it in a 60cm dish, and replace it with phenol red-free DMEM containing 5% CF serum when the cell density reaches 30%-40%. Base treatment, change the medium every 12...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses shRNA for knocking down long-chain non-coding RNAMIR205HG in a targeted manner and an application of the shRNA. The shRNA sequence for knocking down an lncRNA-MIR205HG gene in the targeted manner, which is provided by the invention, can be used for specifically targeting the lncRNA-MIR205HG gene. According to different levels of expression of the lncRNA-MIR205HG in estrogen receptor positive tumor tissues, an MCF7 cell line knocking down the lncRNA-MIR205HG is constructed, the effect of the lncRNA-MIR205HG in estrogen receptor positive breast cancer cell tumor formation is studied, and the result shows that knocking down the lncRNA-MIR205HG can obviously reduce the response degree of MCF7 cells to estrogen and promote estrogen receptor degradation. And the apoptosis, cycle, migration and clone formation ability of MCF7 cells are obviously inhibited. The invention discloses an important role of the lncRNA-MIR205HG in breast cancer pathogenesis, and also provides a new molecular marker and a new drug target for clinical diagnosis, treatment and prognosis monitoring of estrogen receptor positive breast cancer.

Description

technical field [0001] The invention belongs to the field of genetic engineering, and specifically relates to five targeted knockdown sequences of long-chain non-coding RNA MIR205HG, and applications thereof. Background technique [0002] Breast cancer is an epithelial malignancy arising from the terminal ductal lobular unit of the mammary gland. The incidence rate has been slowly increasing in the past 50 years, and it has leapt to the first place among female malignant tumors. The histological type of breast cancer is very complex, pathologically according to the molecular subtype breast cancer can be divided into three negative, estrogen receptor positive (ER + ), Her-2 + Three categories. The pathogenesis of breast cancer has not been fully elucidated, and studies have found that breast cancer is related to the disorder of estrogen secretion in the body. Estrogen is mainly composed of estradiol (E2), which has a variety of biological functions including maintaining s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/113C12N15/867C12N7/01C12Q1/6886A61K31/7088A61P35/00
CPCC12N15/1135C12N15/86C12N7/00C12Q1/6886A61K31/7088A61P35/00C12N2310/14C12N2320/30C12N2740/15021C12N2740/15043C12Q2600/158C12Q2600/178Y02A50/30
Inventor 郭长缨刘丰其张红颖
Owner CHINA PHARM UNIV